Platelet markers that alter significantly in the presence of cancer have been identified as beta-2-microglobulin (B2M), pro-platelet basic protein (PPBP), thymosin beta 4 X-Linked (TMSB4X), and platelet factor 4 (PF4) (111). This evidence concerns the gene B2M and cancer.